153 related articles for article (PubMed ID: 1346163)
1. Cholecystokinin release from the rat caudate-putamen, cortex and hippocampus is increased by activation of the D1 dopamine receptor.
Brog JS; Beinfeld MC
J Pharmacol Exp Ther; 1992 Jan; 260(1):343-8. PubMed ID: 1346163
[TBL] [Abstract][Full Text] [Related]
2. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
Wachtel SR; Hu XT; Galloway MP; White FJ
Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
[TBL] [Abstract][Full Text] [Related]
3. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
4. Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation.
Hu XT; Wachtel SR; Galloway MP; White FJ
J Neurosci; 1990 Jul; 10(7):2318-29. PubMed ID: 1973947
[TBL] [Abstract][Full Text] [Related]
5. Effect of D1- and D2-dopamine agonists on neocortical and hippocampal EEG activity of rat brain: modulation of rimcazole effect.
Verma A; Kulkarni SK; Nayar U
Methods Find Exp Clin Pharmacol; 1993 Oct; 15(8):515-25. PubMed ID: 7905945
[TBL] [Abstract][Full Text] [Related]
6. Microiontophoretic studies of the effects of D-1 and D-2 receptor agonists on type I caudate nucleus neurons: lack of synergistic interaction.
Shen RY; Asdourian D; Chiodo LA
Synapse; 1992 Aug; 11(4):319-29. PubMed ID: 1354398
[TBL] [Abstract][Full Text] [Related]
7. Apparent mediation of the stimulus properties of a low dose of quinpirole by dopaminergic autoreceptors.
Widzowski DV; Cory-Slechta DA
J Pharmacol Exp Ther; 1993 Aug; 266(2):526-34. PubMed ID: 8355188
[TBL] [Abstract][Full Text] [Related]
8. One year of continuous treatment with haloperidol or clozapine fails to induce a hypersensitive response of caudate putamen neurons to dopamine D1 and D2 receptor agonists.
Jiang LH; Kasser RJ; Altar CA; Wang RY
J Pharmacol Exp Ther; 1990 Jun; 253(3):1198-205. PubMed ID: 1972751
[TBL] [Abstract][Full Text] [Related]
9. Trace amines inhibit the electrically evoked release of [3H]acetylcholine from slices of rat striatum in the presence of pargyline: similarities between beta-phenylethylamine and amphetamine.
Baud P; Arbilla S; Cantrill RC; Scatton B; Langer SZ
J Pharmacol Exp Ther; 1985 Oct; 235(1):220-9. PubMed ID: 3930699
[TBL] [Abstract][Full Text] [Related]
10. Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats.
Criswell HE; Johnson KB; Mueller RA; Breese GR
J Pharmacol Exp Ther; 1993 May; 265(2):1001-10. PubMed ID: 8098756
[TBL] [Abstract][Full Text] [Related]
11. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
Hu XT; White FJ
Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
[TBL] [Abstract][Full Text] [Related]
12. Differential influence of D1 and D2 dopamine receptors on acute opiate withdrawal in guinea-pig isolated ileum.
Capasso A; Sorrentino L
Br J Pharmacol; 1997 Mar; 120(6):1001-6. PubMed ID: 9134209
[TBL] [Abstract][Full Text] [Related]
13. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
Sonsalla PK; Manzino L; Heikkila RE
J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
[TBL] [Abstract][Full Text] [Related]
14. Effects of cholecystokinin peptides and GV 150013, a selective cholecystokininB receptor antagonist, on electrically evoked endogenous GABA release from rat cortical slices.
Ferraro L; Beani L; Trist D; Reggiani A; Bianchi C
J Neurochem; 1999 Nov; 73(5):1973-81. PubMed ID: 10537055
[TBL] [Abstract][Full Text] [Related]
15. Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems.
Sonsalla PK; Gibb JW; Hanson GR
J Pharmacol Exp Ther; 1986 Sep; 238(3):932-7. PubMed ID: 2943891
[TBL] [Abstract][Full Text] [Related]
16. Modulation of acetylcholine release by cholecystokinin in striatum: receptor specificity; role of dopaminergic neuronal activity.
Petkova-Kirova P; Giovannini MG; Kalfin R; Rakovska A
Brain Res Bull; 2012 Dec; 89(5-6):177-84. PubMed ID: 22981453
[TBL] [Abstract][Full Text] [Related]
17. Dopamine modulates cholecystokinin release in neostriatum.
Meyer DK; Krauss J
Nature; 1983 Jan; 301(5898):338-40. PubMed ID: 6823307
[TBL] [Abstract][Full Text] [Related]
18. Phorbol esters stimulate the potassium-induced release of cholecystokinin from slices of cerebral cortex, caudato-putamen and hippocampus incubated in vitro.
Allard LR; Beinfeld MC
Biochem Biophys Res Commun; 1988 May; 153(1):372-6. PubMed ID: 3163923
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin and cholecystokinin octapeptide differentially modulate the release of [3H]acetylcholine from caudate nucleus but not cerebral cortex: role of dopamine receptor activation.
Arnerić SP; Reis DJ
Brain Res; 1986 May; 374(1):153-61. PubMed ID: 2872939
[TBL] [Abstract][Full Text] [Related]
20. Release of cholecystokinin from rat midbrain slices and modulatory effect of D2DA receptor stimulation.
Freeman AS; Chiodo LA; Lentz SI; Wade K; Bannon MJ
Brain Res; 1991 Aug; 555(2):281-7. PubMed ID: 1682000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
